• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Vertex - Articles and news items

cystic fibrosis

Exploring the need for mutation-specific treatments in cystic fibrosis

Blog, Z Homepage promo / 1 July 2016 / Caroline Richards, Editor, European Pharmaceutical Review

Here, Caroline Richards, Editor of European Pharmaceutical Review, discusses cystic fibrosis and the treatment options that are currently available or in development…

orkambi

EC grants marketing authorisation for cystic fibrosis drug Orkambi

Industry news / 20 November 2015 / Victoria White

Orkambi (lumacaftor/ivacaftor), authorised for use in patients who have two copies of the F508del mutation, is the first medicine to treat the underlying cause of cystic fibrosis…

vertex-orkambi

FDA approves cystic fibrosis treatment Orkambi

Industry news / 3 July 2015 / Victoria White

The FDA has approved Vertex’s Orkambi, the first medicine to treat the underlying cause of cystic fibrosis in people with two copies of the F508del mutation…

cystic-fibrosis

Data from two Phase 3 studies of cystic fibrosis investigational medicine Orkambi published

Industry news / 18 May 2015 / Victoria White

Data from two Phase 3 studies of Orkambi, an investigational medicine designed to treat the underlying cause of cystic fibrosis, have been published…

 

Webinar: Different thermal analysis techniques to measure the glass transitionWATCH NOW
+ +